Linee guida ESC 2021 per la diagnosi e il trattamento dello scompenso cardiaco acuto e cronico elaborate dalla Task Force per la diagnosi e il trattamento dello scompenso cardiaco acuto e cronico della Società Europea di Cardiologia (ESC) con il contributo straordinario della Heart Failure Association (HFA) dell’ESC
Theresa A. McDonagh, Susanna Price(Royal Brompton Hospital), Michael Böhm(Saarland University), Richard Mindham(European Society of Cardiology), Frank Ruschitzka(Kantonsspital St. Gallen), John G.F. Cleland(University of Glasgow), Claudio Muneretto, María G. Crespo‐Leiro(Complexo Hospitalario Universitario A Coruña), Martine Gilard(Hôpital Maison Blanche), Javed Butler(Jackson Memorial Hospital), John J.V. McMurray(University of Glasgow), Arno W. Hoes(University Medical Center Utrecht), Roy S. Gardner(University of Glasgow), Jelena Čelutkienė(Vilnius University), Tiny Jaarsma(Linköping University), Andrew J.S. Coats(The Heart Research Institute), Marco Metra(Vita-Salute San Raffaele University), Andreas Baumbach(Queen Mary University of London), Mitja Lainščak, Haran Burri, Dimitrios Farmakis(National and Kapodistrian University of Athens), Ovidiu Chioncel(Carol Davila University of Medicine and Pharmacy), Stéphane Heymans(Maastricht University Medical Centre), Carolyn S.P. Lam(University of Glasgow), Marianna Adamo(Surgical Specialties (Canada)), Ewa A. Jankowska(Wroclaw Medical University), Alexandre Mebazaa(Marqueurs cardiovasculaires en situation de stress), Massimo Piepoli(University of Milan), Alexander R Lyon(Royal Brompton Hospital), Anne Kathrine Skibelund(World Economic Forum), Giuseppe M.C. Rosano(Università degli studi di Cassino e del Lazio Meridionale)
Cited by 197
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
2016 European Guidelines on cardiovascular disease prevention in clinical practice
|European Heart Journal|2016|6.5k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k